ECC5004 RBA FE Study in Healthy Participants

Summary

This study is a Phase 1, open-label, randomized, single dose, fixed sequence, crossover study designed to compare the relative bioavailability of 50 mg ECC5004 current tablet formulation (F1) and 50 mg ECC5004 new tablet formulation (F2) under fasted and fed conditions in healthy participants

Timeline

Start

2024-02-06

Primary completion

2024-03-29

Completion

2024-03-29

Drugs

Indications